Nyxoah S.A. (NASDAQ:NYXH) Short Interest Down 17.4% in October

Nyxoah S.A. (NASDAQ:NYXH - Get Free Report) saw a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 58,800 shares, a decline of 17.4% from the October 15th total of 71,200 shares. Based on an average daily volume of 63,200 shares, the days-to-cover ratio is currently 0.9 days. Approximately 0.4% of the company's shares are sold short.

Nyxoah Trading Down 2.5 %

Shares of NASDAQ NYXH traded down $0.21 during trading on Friday, reaching $8.22. The stock had a trading volume of 18,951 shares, compared to its average volume of 49,495. The business's 50-day moving average price is $9.05 and its 200-day moving average price is $8.74. Nyxoah has a fifty-two week low of $4.00 and a fifty-two week high of $20.00. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.95 and a current ratio of 5.28. The company has a market cap of $205.01 million, a P/E ratio of -4.40 and a beta of 1.45.

Institutional Trading of Nyxoah

Several hedge funds have recently made changes to their positions in the business. Kovack Advisors Inc. acquired a new stake in Nyxoah during the 3rd quarter worth approximately $96,000. Ikarian Capital LLC purchased a new position in Nyxoah in the first quarter valued at $684,000. CVI Holdings LLC acquired a new position in Nyxoah during the 2nd quarter worth $1,292,000. Finally, Iron Triangle Partners LP purchased a new stake in Nyxoah during the 1st quarter worth about $3,413,000.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. HC Wainwright cut their price target on shares of Nyxoah from $18.00 to $17.00 and set a "buy" rating for the company in a report on Friday, October 11th. Cantor Fitzgerald reissued an "overweight" rating and set a $16.00 target price on shares of Nyxoah in a research note on Tuesday, November 5th. Finally, Oppenheimer decreased their price target on Nyxoah from $15.00 to $13.00 and set an "outperform" rating on the stock in a research note on Wednesday, August 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Nyxoah currently has a consensus rating of "Buy" and a consensus target price of $17.00.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.